Pancreatic Cancer Research

ResearcherFred and Pamela Buffett Cancer CenterActive in the last 2 years

Satish Sagar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6608-3940; OpenAlex author ID A5050888196. Sources: OpenAlex.

Their work

Papers
10 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2019: 3 papers · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer. First author DOI 10.1016/j.canlet.2026.218927↗
  2. Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. Co-author DOI 10.3390/cancers17060957↗
  3. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6. First author DOI 10.1158/1535-7163.mct-23-0868↗
  4. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. First author DOI 10.3390/ijms23105459↗
  5. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. Co-author DOI 10.1016/j.canlet.2021.01.015↗
  6. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy. Co-author DOI 10.1016/j.ejmech.2021.113579↗
  7. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. First author DOI 10.1016/j.ymthe.2020.12.029↗
  8. The glycoprotein mucin-1 negatively regulates GalNAc transferase 5 expression in pancreatic cancer. First author DOI 10.1002/1873-3468.13532↗
  9. Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells. First author DOI 10.1111/jcmm.14572↗
  10. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer. Co-author DOI 10.1124/jpet.118.255372↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Prakash Radhakrishnan · 10 shared papers, 2019–2026 · strength 1.50
  2. Michael Anthony Hollingsworth · 8 shared papers, 2019–2026 · strength 1.26
  3. Thomas C. Caffrey · 7 shared papers, 2019–2025 · strength 0.97
  4. Christabelle Rajesh · 5 shared papers, 2021–2026 · strength 0.95
  5. Divya Thomas · 5 shared papers, 2019–2021 · strength 0.55
  6. Paul M. Grandgenett · 3 shared papers, 2019–2024 · strength 0.39
  7. Jen Jen Yeh · 2 shared papers, 2021–2022 · strength 0.26
  8. Clara S. Mundry · 1 shared paper, 2026 · strength 0.25
  9. Ying Huang · 1 shared paper, 2026 · strength 0.25
  10. Jayasindu Mathiyazhagan · 1 shared paper, 2025 · strength 0.25
  11. Aaron M. Mohs · 1 shared paper, 2025 · strength 0.25
  12. Eric N. Aguilar · 1 shared paper, 2024 · strength 0.17
  13. Kyle L. McAndrews · 1 shared paper, 2021 · strength 0.13
  14. Premila Devi Leiphrakpam · 1 shared paper, 2021 · strength 0.13
  15. Jered C Garrison · 1 shared paper, 2021 · strength 0.12
  16. Amarnath (Amar) Natarajan · 1 shared paper, 2021 · strength 0.12
  17. Xiang Liu · 1 shared paper, 2021 · strength 0.10
  18. H. Carlo Maurer · 1 shared paper, 2021 · strength 0.10
  19. Kenneth P. Olive · 1 shared paper, 2021 · strength 0.10
  20. Kamiya Mehla · 1 shared paper, 2019 · strength 0.09
  21. Kruti S. Soni · 1 shared paper, 2019 · strength 0.09
  22. Subodh M. Lele · 1 shared paper, 2019 · strength 0.09
  23. Fan Lei · 1 shared paper, 2019 · strength 0.09
  24. Tatiana K. Bronich · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.